Sensory and Motor Systems

Metabotropic Glutamate Receptor 2/3 (mGluR2/3) Activation Suppresses TRPV1 Sensitization in Mouse, But Not Human, Sensory Neurons

Tayler D. Sheahan,1,2 Manouela V. Valtcheva,1,2 Lisa A. McIlvried,1 Melanie Y. Pullen,1 David A.A. Baranger,2,3 and Robert W. Gereau IV1

DOI: http://dx.doi.org/10.1523/ENEURO.0412-17.2018

1Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, 2Washington University Program in Neuroscience, Washington University School of Medicine, St. Louis, Missouri 63110, and 3BRAIN Laboratory, Department of Psychological and Brain Sciences, Washington University in St. Louis, St. Louis, Missouri 63130

Abstract

The use of human tissue to validate putative analgesic targets identified in rodents is a promising strategy for improving the historically poor translational record of preclinical pain research. We recently demonstrated that in mouse and human sensory neurons, agonists for metabotropic glutamate receptors 2 and 3 (mGluR2/3) reduce membrane hyperexcitability produced by the inflammatory mediator prostaglandin E2 (PGE2). Previous rodent studies indicate that mGluR2/3 can also reduce peripheral sensitization by suppressing inflammation-induced sensitization of TRPV1. Whether this observation similarly translates to human sensory neurons has not yet been tested. We found that activation of mGluR2/3 with the agonist APDC suppressed PGE2-induced sensitization of TRPV1 in mouse, but not human, sensory neurons. We also evaluated sensory neuron expression of the gene transcripts forGluR2 (Grm2), mGluR3 (Grm3), and TRPV1 (Trpv1). The majority of Trpv1/H11001 mouse and human sensory neurons expressed Grm2 and/or Grm3, and in both mice and humans, Grm2 was expressed in a greater percentage of sensory neurons than Grm3. Although we demonstrated a functional difference in the modulation of TRPV1 sensitization by mGluR2/3 activation between mouse and human, there were no species differences in the gene transcript colocalization of mGluR2 or mGluR3 with TRPV1 that might explain this functional difference. Taken together with our previous work, these results suggest that mGluR2/3 activation suppresses only some aspects of human sensory neuron sensitization caused by PGE2. These differences have implications for potential healthy human voluntary studies or clinical trials evaluating the analgesic efficacy of mGluR2/3 agonists or positive allosteric modulators.

Key words: Dorsal root ganglia; glutamate; human neurons; metabotropic; nociceptors; pain

Significance Statement

Species differences between rodents and humans have been proposed to contribute to the low success rate of analgesic drug development. This work utilizes primary human neurons to assess the translational potential of metabotropic glutamate receptor 2/3 (mGluR2/3), which have been identified as modulators of pain in a variety of rodent models. In mouse sensory neurons, we found that activation of mGluR2/3 blocked inflammation-induced sensitization of the nonselective cation channel TRPV1. In contrast, this effect was not observed in human sensory neurons. These results indicate that mechanisms of peripheral analgesia are not entirely conserved across species. More broadly, our findings demonstrate that using human tissue to validate analgesic targets identified in rodents is an important step in the translational research process.
Introduction

Species differences between rodents and humans have been proposed to contribute to the low success rate of analgesic drug development (Le Bars et al., 2001; Whiteside and Kennedy, 2010; Woolf, 2010; Mao, 2012). In preclinical research, putative analgesics are often identified and exclusively evaluated in rodent tissues and/or pain models before entering clinical trials, in which such drugs seldom demonstrate efficacy (Kissin, 2010; Woolf, 2010; Moore et al., 2013). Therefore, using primary human neurons to validate preclinical rodent findings is an appealing strategy to improve the translational success of basic pain research findings. With this goal in mind, we and others have established approaches to obtain and use human sensory neurons to better understand human nociceptor physiology (Baumann et al., 1996; Anand et al., 2006; Davidson et al., 2014; Han et al., 2015; Zhang et al., 2015; Sapio et al., 2016; Valtcheva et al., 2016; Rostock et al., 2017).

The group II metabotropic glutamate receptors (mGluRs) have recently been identified as putative targets for pain relief in rodents (Sharpe et al., 2002; Simmons et al., 2002; Yang and Gereau, 2002, 2003; Jones et al., 2005; Du et al., 2008; Osikowicz et al., 2008; Carlton et al., 2009, 2011; Zammataro et al., 2011; Asseri et al., 2015; Kolber, 2015; Chiechio, 2016; Johnson et al., 2017). mGluR2 and mGluR3 are seven transmembrane domain G protein-coupled receptors that decrease cAMP formation, activate potassium channels, and inhibit voltage-gated calcium channels to reduce neuronal excitability and synaptic transmission (Conn and Pin, 1997; Johnson and Schoepf, 2008). Although group II mGluRs are expressed at each level of the pain neuraxis (Petralia et al., 1996; Tang and Sim, 1999; Carlton et al., 2001; Varney and Gereau, 2002; Carlton and Hargett, 2007; Boye Larsen et al., 2014; Kolber, 2015; Chiechio, 2016; Davidson et al., 2016), several lines of evidence suggest that activation of mGlu2 and mGlu3 receptors in peripheral sensory neurons is sufficient for analgesia. For instance, in rodent inflammatory pain models, pharmacological activation of mGluR2/3 expressed on peripheral primary afferents can attenuate pain-like behavior by suppressing sensory neuron sensitization in response to algogens and inflammatory mediators (Yang and Gereau, 2002; Du et al., 2008; Carlton et al., 2011, 2009; Asseri et al., 2015; Davidson et al., 2016). Conversely, pharmacological inhibition of peripheral mGluR2/3 can prolong pain-like behavior and increase sensory neuron activity, suggesting that endogenous activation of mGluR2/3 is analgesic (Yang and Gereau, 2003; Carlton et al., 2011). Given the centrally mediated adverse effects of existing analgesics such as opioid addiction and abuse, peripheral analgesic targets are of particular interest.

Our recent studies on cultured human dorsal root ganglia (DRG) neurons suggest peripheral mGlu2/3 receptors may be clinically relevant analgesic targets. We demonstrated both anatomical and functional expression of group II mGluRs in human DRG (Davidson et al., 2016). Importantly, as in mice, mGluR2/3 activation blocked human nociceptor membrane hyperexcitability produced by the inflammatory mediator prostaglandin E2 (PGE2), indicating that a mechanism for peripheral analgesia may be conserved across species (Davidson et al., 2016). Rodent studies suggest that mGlu2/3 receptors expressed on sensory neuron peripheral terminals can also reduce sensory neuron sensitization by suppressing sensitization of TRPV1 (Yang and Gereau, 2002; Du et al., 2008; Carlton et al., 2009, 2011), a nonselective cation channel that detects noxious stimuli and is critical for inflammation-induced peripheral sensitization (Caterina et al., 1997, 2000; Davis et al., 2000; Moriyama et al., 2005). The present study tested whether the same mechanism is conserved in humans. We used sensory neurons obtained from organ donors without chronic pain to determine whether mGluR2/3 activation blocks inflammation-induced sensitization of TRPV1 in human neurons. We demonstrate that group II mGluR activation suppresses PGE2-induced sensitization of TRPV1 calcium responses in mouse, but not human, sensory neurons. Interestingly, this functional difference was not explained by species differences in coexpression of the TRPV1 gene transcript with mGlu2 or mGlu3 receptor gene transcripts.

Materials and Methods

Animals

All experiments were performed in compliance with protocols approved by the Animal Studies Committee of Washington University in St. Louis (Protocol nos. 20150246 and 20160097). Experiments were conducted on 5–8-wk-old C57BL/6J male and female mice (Jackson Laboratory, RRID:IMSR_JAX:000664). Mice were housed in an animal facility with a 12-h light-dark cycle and given food and water ad libitum.

Donors

Human tissue was obtained in compliance with procedures approved by Mid-America Transplant (St. Louis, Missouri).
DRG neurons, satellite glial encased neurons, and thus accurate physiology experiments could not be performed until the glial peeled off and exposed the neuron plasma membrane, which occurred after 3–4 DIV as reported previously (Valtcheva et al., 2016). Mouse calcium imaging experiments were therefore initially performed on DIV 4. Strikingly, we found that only 2% of mouse DRG neurons responded to 100 nM capsaicin on DIV 4, which we interpreted as a functional downregulation of TRPV1. Therefore, we chose to perform mouse calcium imaging experiments on DIV 2 such that recordings were not performed acutely after culturing neurons, yet were completed before TRPV1 functional downregulation.

Cultured neurons from mice and humans were incubated with 3 μg/mL of the ratiometric calcium indicator Fura-2 AM (Life Technologies) for 45 min. Neurons were then incubated in external solution for 15 min to allow for de-esterification of Fura-2 AM. External solution consisted of (in mM): 130 NaCl, 5 KCl, 2 CaCl₂, 1 MgCl₂, 30 glucose, and 10 Hepes. For recordings, coverslips were placed into a chamber and perfused with room temperature external solution. Cells were viewed under an inverted microscope (Olympus Optical), and fluorescent images were acquired every 2 s using a Hamamatsu ORCA camera (Hamamatsu). SimplePCI Software (HCImage, Hamamatsu) was used to identify regions of interest surrounding Fura-2 AM–loaded neurons a priori and to record fluorescence emission at alternating excitation wavelengths of 357 and 380 nm.

The experimental protocol entailed a 2-min baseline in external solution followed by a 20-s bath application of 100 nM capsaicin (Sigma-Aldrich), a 3-min wash with external solution, then a treatment condition entailing application of either 7 min of vehicle (external solution), 6 min of 1 μM prostaglandin E2 (PGE₂, Tocris), or 1 min of 10 μM (2R, 4R)-4-aminopyrrolidine-2,4-dicarboxylate (APDC, Tocris) alone followed by 6 min of 10 μM APDC plus 1 μM PGE₂. Immediately after treatment, a second pulse of 100 nM capsaicin was bath-applied, neurons were washed for 6 min with external solution, and a 10-s pulse of 50 mM KCl was applied to test for cell viability. At least 2 treatment conditions were tested for a given mouse or donor tissue preparation. All drugs were diluted in external solution and bath-applied at a rate of 2 mL/min. Stock solutions of 2.8 mM PGE₂ and 10 mM APDC were made up in DMSO and water, respectively. Peak calcium responses were calculated by dividing the absolute increase in Fura-2 AM signal after stimulus application by the proceeding 30-s baseline Fura-2 AM signal. The response threshold to capsaicin was defined as an increase of ≥10% from baseline signal. Cells that did not respond to high KCl were excluded from calcium imaging analysis.

Fluorescent in situ hybridization (RNAscope)

At the conclusion of mouse and human calcium imaging experiments, neurons were fixed on ice with 4% paraformaldehyde/4% sucrose for 15 min and washed with PBS. Fluorescent in situ hybridization (FISH) studies were performed according to the protocol for cultured adherent cells using the RNAscope Multiplex Fluorescent Assay

---

**Table 1. Donor information and tissue uses**

| Donor Age, y | Sex | Race | Cause              | Tissue uses          |
|--------------|-----|------|--------------------|----------------------|
| 1            | 21  | Male | White              | Stroke Ca²⁺ imaging  |
| 2            | 55  | Female | White              | Stroke Ca²⁺ imaging, FISH |
| 3            | 22  | Male | Black              | Anoxia Ca²⁺ imaging  |
| 4            | 44  | Female | White              | Stroke Ca²⁺ imaging  |
| 5            | 12  | Female | White              | Anoxia Ca²⁺ imaging, FISH |
| 6            | 26  | Male | White              | Head trauma Ca²⁺ imaging, FISH |
| 7            | 18  | Female | White              | Head trauma Ca²⁺ imaging, FISH |
| 8            | 18  | Male | White              | Head trauma Ca²⁺ imaging, FISH |

y, year; FISH, fluorescent in situ hybridization.
(Advanced Cell Diagnostics) with minor modifications. After dehydration and rehydration of cells in ethanol, glass coverslips were mounted onto glass slides using ethyl cyanoacrylate. Neurons were treated with protease III diluted 1:10 (mouse) or 1:5–7.5 (human) at room temperature for 10 min. Species-specific target probes for Trpv1, Grm2, and Grm3 (Table 2) were combined, applied to neurons, and allowed to hybridize for 2 h at 40°C in a humidified oven. A series of incubations were then performed to amplify hybridized probe signal and label target probes with the assigned fluorescence detection channel (C1–C3). Coverslips were counterstained with DAPI using ProLong Gold Antifade Mountant (Invitrogen). Neurons were imaged at 40× using a Leica SPE confocal microscope (Leica Microsystems). Fields of interest were identified in the DAPI channel. Fiji (Image J, NIH, RRID: SCR_015654) software was used to calculate neuron diameter and manually quantify single RNA molecule signals. In the RNAscope assay, each punctate dot represents a single target RNA molecule. However, to reduce the likelihood of false positives, mouse and human neurons were defined as positive for a given RNA target if they had ≥4 or ≥2 puncta, respectively, based on the range in neuron puncta density observed for each species. Although we used the same mouse and human tissues used in both assays (Table 1), neuron populations analyzed using FISH were not identical to those analyzed via calcium imaging.

### Table 2. RNAscope probes used for FISH

| Target                | Catalog no.    |
|-----------------------|----------------|
| Mm-Trpv1              | 313331         |
| Mm-Grm2-C3            | 317831-C3      |
| Mm-Grm3-C2            | 317821-C2      |
| Positive Control Probe-Mm | 320881     |
| Hs-Trpv1              | 415381         |
| Hs-GRM2-C3            | 589771-C3      |
| Hs-GRM3-C2            | 500181-C2      |
| Positive Control Probe-Hs | 320861     |
| Negative Control Probe | 320871         |

Mm, mus musculus; Hs, homo sapiens; C2, channel 2; C3, channel 3.

### Table 3. Statistical analysis

| Location | Data Structure                  | Type of Test | Comparison          | 95% confidence interval |
|----------|---------------------------------|--------------|---------------------|-------------------------|
| a        | Non-normally distributed        | t test       | Vehicle vs. PGE2    | -0.6862 to -0.2728      |
| b        | Non-normally distributed        | t test       | PGE2 vs. PGE2 + APDC| 0.1317 to 0.618         |
| c        | Non-normally distributed        | t test       | Vehicle vs. PGE2    | -0.2736 to 0.06428      |
| d        | Non-normally distributed        | t test       | Vehicle vs. PGE2    | -0.5774 to -0.2563      |
| e        | Non-normally distributed        | Regression   | PGE2 vs. PGE2 + APDC| 0.4204 to 0.2717        |
| f        | Categorical                     | Chi-squareda | Vehicle vs. PGE2    | -0.7953 to -0.1871      |
| g        | Mouse: non-normally distributed | t test       | Vehicle vs. PGE2 vs. PGE2 + APDC | -0.1178 to 0.1284 |
| h        | Categorical                     | Chi-squareda | Mouse vs. human     | 0.5621 to 0.8235        |
| i        | Categorical                     | Chi-squareda |                     | 2.653 to 4.769          |
| j        | Categorical                     | Chi-squareda |                     | 1.846 to 3.855          |

*Odds ratio confidence interval reported.

The D’Agostino and Pearson normality test was performed, when applicable.

## Results

**mGlur2/3 suppress PGE2-induced TRPV1 sensitization in mouse, but not human, sensory neurons**

TRPV1 is sensitized by the cAMP/PKA pathway, which is stimulated by inflammatory mediators such as PGE2 (Lopshire and Nicol, 1998; De Petrocellis et al., 2001; Bhave et al., 2002; Mohapatra and Nau, 2003; Meves, 2006). In contrast, group II mGlur receptor activation inhibits adenylyl cyclase and subsequent cAMP production (Conn and Pin, 1997; Johnson and Schoepf, 2008). To determine whether mGlur2/3 activation blocks TRPV1 sensitization, we quantified capsaicin-induced calcium responses of mouse and human sensory neurons. Two 20-s pulses of 100 nm capsaicin were bath-applied to DRG neurons, and the degree of TRPV1 sensitization was defined as the response ratio of the peak of the second capsaicin response divided by the peak of the first cap-
Under vehicle conditions, TRPV1 desensitization is observed in both mouse and human DRG neurons in the form of reduced calcium responses to subsequent capsaicin pulses (Fig. 1A, B). In mouse sensory neurons, bath application of PGE2 between capsaicin pulses significantly increased the capsaicin response ratio compared with vehicle (Fig. 1B, C). Coapplication of APDC with PGE2 blocked this effect and significantly reduced the response ratio compared to PGE2 alone (p = 0.0081; n = 89–150 neurons, n = 3–4 preps/condition). D, PGE2 also significantly increased the capsaicin response ratio of human DRG neurons compared with vehicle (p = 3.0 × 10^{-6}; n = 59–71 neurons, n = 5–6 donors/condition); whereas coapplication of APDC did not suppress PGE2-induced increases in the capsaicin response ratio (p = 1, n = 59–64 neurons, n = 6 donors/condition), which remained significantly greater than vehicle (p = 0.0053, n = 64–71 neurons, n = 5–6 donors/condition). Capsaicin response ratios were compared using unpaired t tests and a Bonferroni correction for multiple comparisons. Data are presented as mean ± SEM. E, Compared with those of mice, a greater percentage of human DRG neurons responded to 100 nM capsaicin (χ^2 = 15.45, p = 8.5 × 10^{-6}; mouse: 405/1761 neurons, n = 4 preps, human: 223/731 neurons, n = 8 donors). F, LMM regression correction for impact of individual donor, as well as donor age and sex, did not alter human capsaicin response ratio analysis statistical outcomes compared with t tests alone.
responses. Consistent with the effects on capsaicin peak response ratios, application of PGE$_2$ significantly increased AUC compared with vehicle, and coapplication of APDC with PGE$_2$ significantly reduced this effect (data not shown). These findings confirm our previously published work in cultured sensory neurons obtained from CD-1 mice in which we also demonstrated that suppression of PGE$_2$-induced TRPV1 sensitization by APDC is blocked by the group II mGluR antagonist LY341495, and thus is attributable to mGlu2/3 receptor activation (Yang and Gereau, 2002).

In human sensory neurons, we found that although application of PGE$_2$ between capsaicin pulses significantly increased the capsaicin response ratio compared with vehicle, the response ratio after coapplication of APDC with PGE$_2$ did not significantly differ from application of PGE$_2$ alone (Fig. 1B, D$^{c,d}$). We observed similar results for total calcium load of capsaicin responses (data not shown). Unlike rodents used in preclinical studies, human organ donors display wide demographic and genetic diversity. To correct for between-donor heterogeneity, we performed a LMM regression. As the effect of age and sex on human sensory neuron physiology is of broad interest to pain researchers, these parameters were included as covariates in our LMM regression. Interestingly, we found that correcting for impact of individual donor, as well as donor age and sex, did not alter our capsaicin response ratio outcome (Fig. 1F). Moreover, LMM regression analysis indicated that the day in vitro at which calcium imaging experiments were performed did not influence capsaicin response ratios for any of the conditions tested ($t = 0.105, p = 0.9182$). Taken together, these results demonstrate that mGluR2/3 activation suppresses PGE$_2$-induced TRPV1 sensitization in mouse, but not human, sensory neurons.

We were also interested in whether the same percentage of mouse and human sensory neurons respond to capsaicin. A neuron was defined as capsaicin responsive if it responded to either the first or second pulse of capsaicin. Notably, compared with vehicle conditions, application of PGE$_2$ did not increase the number of neurons that did not respond to the first pulse of capsaicin but did respond to the second pulse of capsaicin in either species. Therefore, data were pooled across treatment conditions for calculations of percentage of capsaicin-responsive neurons. Of the total number of sensory neurons evaluated in calcium imaging studies, 23.0% of mouse sensory neurons versus 30.5% of human sensory neurons responded to 100 nM capsaicin, indicating that human sensory neurons are modestly more capsaicin responsive (Fig. 1E). These results are consistent with our initial observations that human sensory neurons exhibit greater chemosensitivity to algogens and pruritogens compared with rodents (Davidson et al., 2014). In the present study, we chose to use 100 nM capsaicin to test for modulation of TRPV1 desensitization. Previous studies using higher concentrations of capsaicin (200 nM to 1 µM) indicate that capsaicin elicits calcium responses in a greater proportion of mouse DRG and trigeminal neurons, ranging from 30% to 70% (Davis et al., 2000; Elitt et al., 2008; Barabas and Stucky, 2013; Ren et al., 2014; Valtcheva et al., 2015; Mohammed et al., 2017).

### Mouse and human sensory neurons share similar Trpv1, Grm2, and Grm3 expression and coexpression profiles

We hypothesized that the observed species differences in mGluR2/3 functional modulation of TRPV1 could be due to reduced coexpression between TRPV1 and mGlu2 and/or mGlu3 receptors in human versus mouse sensory neurons. We previously demonstrated mGluR2 immunoreactivity in human sensory neurons (Davidson et al., 2016). However, because of the lack of highly selective mGluR3 antibodies suitable for immunohistochemistry (Garcia-Bea et al., 2016), we assessed expression of TRPV1, mGluR2, and mGluR3 mRNA transcripts (referred to as Trpv1, Grm2, and Grm3, respectively) in dissociated sensory neurons using RNAscope FISH. The mouse DRG neurons evaluated in FISH studies ranged from 10.0 to 35.5 µm in diameter, with a mean diameter of 17.7 ± 0.2 µm for the total population and 20.3 ± 0.4 µm for TRPV1$^+$ neurons (Fig. 2A). In comparison, human DRG neurons ranged from 10.0 to 56.3 µm in diameter, with a mean diameter of 31.9 ± 0.5 µm for the total population and 33.9 ± 0.9 µm for TRPV1$^+$ neurons (Fig. 2B). The mean diameter of the total human DRG neuron population was significantly larger than that of mice (Fig. 2C). Our findings closely resemble the size distribution of mouse DRG neurons reported previously (Dirajial et al., 2003; Barabas et al., 2012; O’Brien et al., 2015). Previous human studies show that the average sensory neuron diameter in unfixed tissues is between ~40 and 60 µm (Anand et al., 2006; Davidson et al., 2014; Xu et al., 2015; Han et al., 2016; Zhang et al., 2017), further highlighting the species difference in sensory neuron size.

With respect to mRNA expression, of the total population of mouse DRG neurons, 37.2% of neurons were positive for the Trpv1 gene transcript, 61.5% were positive for Grm2, and 30.9% were positive for Grm3 (Fig. 2D). Similar transcript expression was observed in human sensory neurons, with 32.2% of all neurons positive for TRPV1, 52.7% positive for GRM2, and 29.5% positive for GRM3 (Fig. 2E). Notably, a significantly greater percentage of total DRG neurons expressed Grm2 compared to Grm3 in both mice ($\chi^2 = 74.56, p = 1.0 \times 10^{-15}$ h) and humans ($\chi^2 = 28.83, p = 8.0 \times 10^{-8}$). Although there was a trend toward an increased percentage of Grm2$^+$ neurons in mouse compared with human DRG ($\chi^2 = 2.229$ with Bonferroni correction, $p = 0.077$), there were no significant species differences in the expression of the transcripts of interest.

Analysis of transcript coexpression showed that the majority of TRPV1$^+$ mouse DRG neurons coexpressed Grm2, Grm3, or both. To elaborate, 33.3% of TRPV1$^+$ neurons coexpressed Grm2, 7.5% coexpressed Grm3, and 44.2% coexpressed both Grm2 and Grm3 (Fig. 2F). Of TRPV1$^+$ human DRG neurons, 41.0% coexpressed GRM2, 8.4% coexpressed GRM3, and 32.5% coexpressed both GRM2 and GRM3 (Fig. 2G). No significant species differences were observed in the coexpression of Trpv1 with Grm2.
and/or Grm3 gene transcripts. Thus, these findings suggest that the absence of mGluR2/3-induced suppression of TRPV1 sensitization in human DRG neurons cannot be explained by reduced coexpression of TRPV1 with group II mGluRs at the gene transcript level.

**Discussion**

Peripheral targets for pain relief are greatly desired given the centrally mediated side effects, including addiction and misuse of current frontline analgesics such as opioids. In both mice and humans, activation of group II mGluRs blocks sensory neuron membrane hyperexcitability elicited by the inflammatory mediator PGE2 (Davidson et al., 2016). In the present study, we demonstrate that suppression of inflammation-induced TRPV1 sensitization represents an additional mechanism by which mGluR2/3 reduce peripheral sensitization in mouse, but not human, sensory neurons. We further show equivalent colocalization of Trpv1 with Grm2 and Grm3 mRNA transcripts in mouse and human DRG neurons, suggesting that disparities in coexpression do not explain species differences in the functional modulation of TRPV1 by group II mGluRs. These findings indicate that although mGluR2/3 activation decreases sensory neuron sensitization in both mice and humans, mechanisms of peripheral analgesia are not fully conserved across species.

**mGluR2/3 functional differences in mouse and human sensory neurons**

That the mGlu2/3 receptor agonist APDC did not suppress PGE2-induced TRPV1 sensitization in human DRG neurons was a surprising observation. Foremost, cDNA and amino acid sequences of human and rodent mGluR2 and mGluR3 display at least 90% homology (Flor et al., 1995; Makoff et al., 1996; Johnson and Schoepp, 2008). In turn, APDC exhibits comparable potency at rodent and human group II mGluRs with respect to inhibition of stimulated cAMP responses (Schoepp et al., 1995). Our recent
finding that APDC decreases excitability and increases action potential threshold in PGE₂-treated sensory neurons of both species further suggests mGluR2/3 functional homology in mouse and human sensory neurons (Davidson et al., 2016). Existing behavioral and in vitro rodent studies strongly suggest that inhibition of cAMP-dependent TRPV1 sensitization is another mechanism by which mGluR2/3 can block sensory neuron sensitization (Yang and Gereau, 2002; Du et al., 2008; Carlton et al., 2009, 2011). Here, we substantiate these findings by demonstrating that APDC blocks PGE₂-induced TRPV1 sensitization in C57BL/6J mice. However, this observation did not translate in human sensory neurons despite the apparent similarities of mGluR2/3 function between species.

There are multiple potential explanations for the lack of translation of mGluR2/3 functional modulation of TRPV1 from mice to humans. For example, in addition to PKA, PGE₂-induced intracellular signaling cascades can activate other kinases known to sensitize TRPV1, including PKC and c-Src kinase (Vellani et al., 2001; Numazaki et al., 2002; Jin et al., 2004; Moriyama et al., 2005). Thus, although we observed PGE₂-induced sensitization of capsaicin responses in both mouse and human sensory neurons, it is possible that in contrast to mice, PGE₂-induced TRPV1 sensitization in humans occurs via a predominantly PKA-independent pathway that is not influenced by mGlu2/3 receptor activation. Further investigation of the intracellular mechanisms that underlie PGE₂-induced TRPV1 sensitization in human sensory neurons is therefore needed.

Another important consideration is that although we observed equivalent coexpression of Grm2 and Grm3 gene transcripts in Trpv1⁻/⁻ mouse and human DRG neurons, whether equivalent coexpression of TRPV1 and mGluR2/3 also extends to the protein level remains unclear. For instance, it is possible that species differences exist in the regulation of translation, posttranslational modifications, and subcellular compartmentalization of TRPV1 and mGlu2/3 receptors. TRPV1 immunoreactivity has been demonstrated in human DRG neurons, peripheral nerves, and intra-epidermal nerve fibers (Anand et al., 2006, 2015; Facer et al., 2007; Li et al., 2015; Han et al., 2016). However, until selective mGluR2 and mGluR3 antibodies suitable for immunohistochemistry are generated, we are able to evaluate the coexpression and subcellular localization of group II mGluRs with TRPV1 remains limited. Importantly, although mGlu2/3 receptor activation does not modulate sensitization of TRPV1 in humans, the expression of GRM2 and/or GRM3 in the majority of small-diameter (<50 μm) TRPV1⁻/⁻ human DRG neurons suggests that these receptors are well positioned to modulate nociceptor activity by alternative mechanisms. Thus, mGluR2/3 remain putative human peripheral analgesic targets.

**Sensory neuron expression of Grm2, Grm3, and Trpv1**

Existing immunohistochemical analyses of rodent DRG neurons demonstrate high colocalization of group II mGlu receptors with TRPV1, with 93% of TRPV1-positive neurons expressing mGluR2/3 and effectively all mGluR2/3-positive neurons expressing TRPV1 (Carlton et al., 2009). Here we demonstrate that the majority (≥81%) of Trpv1⁻/⁻ mouse and human sensory neurons also express Grm2 and Grm3 gene transcripts. In contrast, we found that in both mice and humans, only a subset (45%–62%) of either Grm2⁻/⁻ or Grm3⁻/⁻ neurons also expressed the Trpv1 transcript. Importantly, prior immunohistochemistry studies using nonselective mGluR2/3 antibodies and RNA-sequencing analysis of homogenized DRG precluded analyses of which group II mGlu receptor is predominantly expressed in sensory neurons and to what extent mGluR2 and mGluR3 are coexpressed within the same neurons. We show for the first time that Grm2 is more highly expressed than Grm3 in mouse and human sensory neurons. Further, while Grm2 and Grm3 are coexpressed in a subset (38%–77%) of mouse and human sensory neurons, the transcripts are also expressed individually. These findings suggest that mGluR2 may play a larger role in modulating nociceptor excitability than mGluR3. Indeed, previous behavioral studies demonstrate that the analgesic efficacy of group II mGlu receptor agonists persists in mGluR3⁻/⁻, but not mGluR2⁻/⁻, mice, suggesting a greater role for mGluR2 than mGluR3 in pain regulation (Zammataro et al., 2011). As repeated dosing with group II mGlu receptor agonists causes analgesic tolerance in rodents (Jones et al., 2005; Chiechio et al., 2009), alternative strategies to reinforce endogenous activation of mGluR2 may be required to effectively target group II mGlu receptors for clinical pain relief. Our results suggest that recently developed mGluR2-specific positive allosteric modulators may be promising agents for blockade of peripheral sensitization (Galici et al., 2006; Asseri et al., 2015).
complete comparisons between species, and perhaps more interestingly, among donor subpopulations.

Nevertheless, while only a small number of comparative studies of rodent and human sensory neurons have been conducted, it is becoming increasingly clear that species differences exist in gene expression, ion channel properties, and action potential firing patterns (Baldo et al., 2013; Han et al., 2015; Chang et al., 2017; Ray et al., 2017; Rostock et al., 2017; Zhang et al., 2017). Therefore, human sensory neurons represent a vital tool for improving our understanding of human nociceptor physiology under both normal and pathologic conditions. Further, using human sensory neurons to assess the validity of putative analgesic targets identified in rodents may lead to increased translational success of preclinical findings.

References
Anand U, Otto WR, Casula MA, Day NC, Davis JB, Bountra C, Birch R, Anand P (2006) The effect of neurotrophic factors on morphology, TRPV1 expression and capsaicin responses of cultured human DRG sensory neurons. Neurosci Lett 399:51–56. CrossRefMedline
Anand U, Liangou Y, Sinisi M, Fox M, MacQuillan A, Quick T, Korchev YE, Bountra C, McCarthy T, Anand P (2015) Mechanisms underlying cytolytic efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain 11:38. CrossRefMedline
Asseri KA, Puli E, Schwarz SKW, MacLeod BA (2015) Group II metabotropic glutamate receptor antagonism prevents the antiallodynic effects of R-isovaline. Neuroscience 293:151–156. CrossRef
Baldo G, Wozniak DF, Oehlemiller KK, Zhang Y, Giugliani R, Ponder KP (2013) Retroviral-vector-mediated gene therapy to mucopoly-saccharidosis I mice improves sensorimotor impairments and other behavioral deficits. J Inherit Metab Dis 36:499–512. CrossRefMedline
Barbas ME, Kossyreve EA, Stucky CL (2012) TRPA1 is functionally expressed primarily by IB4-binding, non-peptidergic mouse and rat sensory neurons. PLoS One 7:1–12. CrossRef
Barbas ME, Stucky CL (2013) TRPV1, but not TRPA1, in primary sensory neurons contributes to cutaneous incision-mediated hyperalgesia. Mol Pain 9:9. CrossRef
Bates D, Mächler M, Bolker B, Walker S (2014) Fitting linear mixed-effects models using lme4. J Stat Softw 67:1–48.
Baumann TK, Burchiel KJ, Ingram SL, Martenson ME (1996) Responses of adult human dorsal root ganglion neurons in culture to capsaicin and low pH. Pain 65:31–38. Medline
Baumann TK, Chaudhry P, Martenson ME (2004) Background potassium channel block and TRPV1 activation contribute to proton depolarization of sensory neurons from humans with neuropathic pain. Eur J Neurosci 19:1343–1351. CrossRef
Bhave G, Zhu W, Wang H, Brasier D, Oxford GS, Gereau RW (2002) Capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in response of adult human dorsal root ganglion neurons with special focus on Nav1.7, species differences, and regulation by paclitaxel. Neuros Bull 1–9.
Chiocchio S (2016) Modulation of chronic pain by metabotropic glutamate receptors. Adv Pharmacol 75:63–89. CrossRefMedline
Chiocchio S, Zammataro M, Morales ME, Busceti CL, Drago F, Gereau RW, Copani A, Nicoletti F (2009) Epigenetic modulation of mGlur2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. Mol Pharmacol 75:1014–1020. CrossRefMedline
Chung W, Berta T, Kim YH, Lee S, Lee SY, Ji RR (2017) Expression and role of voltage-gated sodium channels in human dorsal root ganglion neurons with special focus on Nav1.7, species differences, and regulation by paclitaxel. Neuros Bull 1–9.
García-Bea A, Walker MA, Hyde TM, Kleinman JE, Harrison PJ, Lane TA (2016) Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: antibody characterisation and a semiquantitative western blot study. Schizophr Res 177:18–27. CrossRef

Han C, Estacion M, Huang J, Vasylyev DV, Zhao P, Dib-Hajj S, Waxman SG (2015) Human Nav1.8: enhanced persistent and ramp currents contribute to distinct firing properties of human DRG neurons. J Neurophysiol 113:3172–3185. CrossRef

Han Q, Kim YH, Wang X, Liu D, Zhang ZJ, Bey AL, Lay M, Chang W, Berta T, Zhang Y, Jiang YH, Ji RR (2016) SHANK3 deficiency impairs heat hyperalgesia and TRPV1 signaling in primary sensory neurons. Neuron 92:1279–1293. CrossRef Medline

Jin X, Morsy N, Winston J, Pasricha PJ, Garrett K, Akbarali HI (2004) Modulation of TRPV1 by nonreceptor tyrosine kinase, c-Src kinase. Am J Physiol Cell Physiol 287:C558–C563. CrossRef Medline

Johnson M, Schoepp DD (2008) Group II metabotropic glutamate receptors (mGlu2 and mGlu3). In: Gereau RW, Swanson G, editors. The Glutamate Receptors. Totowa, NJ: Humana Press, 2008; pp. 465–488.

Johnson MP, Muhlhauser MA, Nisenbaum ES, Simmons RMA, Foster BM, Knopp KL, Yang L, Morrow D, Li DL, Kennedy JD, Swanson S, Monn JA (2017) Broad spectrum efficacy with LY2934747, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2969822, in rodent pain models. Br J Pharmacol 174:822–835. CrossRef

Jones CK, Eberle EL, Peters SC, Monn JA, Shannon HE (2005) Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology 49:206–218. CrossRef

Kissin I (2010) The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg 110:780–789. CrossRef Medline

Kolber BJ (2015) mGluRs head to toe in pain. Prog Mol Biol Transl Sci 131:281–324. CrossRef Medline

Le Bars D, Gozariu M, Cadden SW (2001) Animal models of nociception. Pharmacol Rev 53:597–652. Medline

Li Y, et al. (2015) The cancer chemotherapeutic paclitaxel increases currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J Biol Chem 278:50080–50090. CrossRef Medline

Meves H (2006) The action of prostaglandins on ion channels. Curr Neuropharmacol 4:41–57. Medline

Mohapatra DP, Nau C (2003) Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J Biol Chem 278:50080–50090. CrossRef Medline

Moon A, Derry S, Eccleston C, Kalso E (2013) Expect analgesic failure; pursue analgesic success. Br Med J 346:2690. CrossRef

Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga T, Narumiya S, Tominaga M (2005) Sensitization of TRPV1 by EP 1 and IP receptors reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 1:3. CrossRef

Numazaki M, Tominaga T, Toyooka H, Tominaga M (2002) Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cε and identification of two target serine residues. J Biol Chem 277:13375–13378. CrossRef Medline

O’Brien DE, Alter BJ, Satomoto M, Morgan CD, Davidson S, Vogt SK, Norman ME, Gereau GB, Demaro JA, Landreth GE, Golden JP, Gereau RW (2015) ERK2 alone drives inflammatory pain but cooperates with ERK1 in sensory neuron survival. J Neurosci 35:9491–9507. CrossRef

Osisikowicz M, Mika J, Makuch W, Przewlocka B (2008) Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain. Pain 139:117–126. CrossRef

Petralia RS, Wang Y-X, Niedzielski AS, Wenthold RJ (1996) The metabotropic glutamate receptors, MGLUR2 and MGLUR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 71:949–976. Medline

R Core Team (2017) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.

Ray P, Torck A, Quigley L, Wangzhou A, Neiman M, Price TJ (2017) Comparative transcriptome profiling of the human and mouse dorsal root ganglia: An RNA-seq-based resource for pain and sensory neuroscience research. bioRxiv doi: https://doi.org/10.1101/165431.

Ren A-J, Wang K, Zhang H, Liu A, Ma X, Liang Q, Cao D, Wood JN, He DZ, Ding Y-Q, Yuan W-J, Xie Z, Zhang WJ (2014) ZBTB20 regulates nociception and pain sensitivity by modulating TRP channel expression in nociceptive sensory neurons. Nat Commun 5:4984. CrossRef Medline

Rostock C, Schrenk-Sierness K, Pohle J, Siarness J (2017) Human vs. mouse nociceptors—similarities and differences. Neuroscience CrossRef Medline

Sapio MR, Goswami SC, Gross JR, Mannes AJ, Iadaraola MJ (2016) Transcriptional analyses of genes and tissues in inherited sensory neuropathies. Exp Neurol 283:375–395. CrossRef Medline

Schoepp DD, Johnson BG, Salhoff CR, Valu MJ, Desai MA, Burnett JP, Mayne NG, Monn JA (1995) Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4-dicarb oxylate. Neuropharmacology 34:843–850. CrossRef

Sharpe EF, Kingston AE, Lodge D, Monn JA, Headley PM (2002) Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo. Br J Pharmacol 135:1255–1262. CrossRef Medline

Simmons RMA, Webster AA, Kaira AB, Iyengar S (2002) Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem Behav 73:419–427. CrossRef

Tang FR, Sim MK (1999) Pre- and/or post-synaptic localisation of metabotropic glutamate receptor 1a (mGluR1a) and 2/3 (mGluR2/3) in the rat spinal cord. Neurosci Res 34:73–78. Medline

Valkcheva MV, Copits BA, Davidson S, Sheahan TD, Pullen MY, Vellani V, Mapplebeck S, Moriondo A, Davis JB, McNaughton PA, Simmons RMA, Varney MA, Gereau RW (2002) Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr Drug Targets CNS Neurol Disord 1:283–286. CrossRef

Vellani V, Mapplebeck S, Moriondo A, Davis JB, McNaughton PA (2001) Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol 534:813–825. Medline

Whiteside GT, Kennedy J (2010) Consideration of pharmacokinetic pharmacodynamic relationships in the discovery of new pain drugs. In: Kruger L, Light A, editors. Translational Pain Research:
Yang D, Gereau RW (2002) Peripheral group II metabotropic glutamate receptors (mGluR2/3) regulate prostaglandin E2-mediated sensitization of capsaicin responses and thermal nociception. J Neurosci 22:6388–6393. Medline

Yang D, Gereau RW (2003) Peripheral group II metabotropic glutamate receptors mediate endogenous anti-allodynia in inflammation. Pain 106:411–417. Medline

Zammataro M, Chiechio S, Montana MC, Traficante A, Copani A, Nicoletti F, Gereau RW (2011) mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists. Mol Pain 7:6. CrossRef Medline

Zhang X, Priest BT, Belfer I, Gold MS (2017) Voltage-gated Na+ currents in human dorsal root ganglion neurons. eLife 6:1–23. CrossRef Medline

Zhang XL, Lee KY, Priest BT, Belfer I, Gold MS (2015) Inflammatory mediator-induced modulation of GABAA currents in human sensory neurons. Neuroscience 310:401–409. CrossRef Medline